This article is more than 5 years old. Information may no longer be current.
Study commences on new keratoconus refractive correction treatment
Click Here to Manage Email Alerts
Avedro Inc. and Hersh Vision Group recently announced that the first patient has been treated in a physician-sponsored investigational new drug study for the safety and efficacy of the Keraflex Microwave System, according to an Avedro press release.
“Keraflex, combined with corneal collagen cross-linking, is a promising new technology to flatten the protruding cone of keratoconus and make the irregular cornea smoother. This should help improve contact lens wear and vision with glasses in patients with keratoconus. We hope that Keraflex can help avoid cornea transplants in many patients who otherwise might have no other alternative,” Peter Hersh, MD, said in the release.
The Keraflex refractive correction treatment takes less than a second and is enhanced through a subsequent treatment of corneal collagen cross-linking using Avedro’s KXL accelerated cross-linking system, the release said.
Keraflex has received the CE Mark and is commercially available in more than 30 countries but is currently not approved for use in the U.S.